Symptomatic hypotension with venlafaxine–benzodiazepine interaction

REFERENCES

• Beauclair L, Radoi-Androus D, Chouinard G (2000) Selective serotonin-noradrenaline reuptake inhibitors. In: Sadock BJ, Sadock VA (eds) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 7th edn. Philadelphia: Lippincott/Williams & Wilkins: 2427–32.
   Google Scholar
• Montgomery SA (1993) Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 54: 119–26.
   PubMed Web of Science ®Google Scholar
• Cohen LJ (1997) Rational drug use in the treatment of depression. Pharmacotherapy 17: 45–61.
   PubMed Web of Science ®Google Scholar
• Ballenger JC (2000) Benzodiazepine receptor agonists and antagonists. In: Sadock BJ, Sadock VA (eds) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 7th edn. Philadelphia: Lippincott/Williams & Wilkins: 2317—24.
   Google Scholar
• Ereshefsky L (1996) Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 3 (suppl 2): 37—50.
   Google Scholar
• Cusack B, Nelson A, Richelson E (1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 114: 559–65.
   PubMed Web of Science ®Google Scholar
• Howell SR, Husbands GEM, Scatina JA, Sisenwine SF (1993) Metabolic disposition of C-venlafaxine in mouse, rat, dog, rhesus, monkey and man. Xenobiotica 23: 349—59.
   PubMed Web of Science ®Google Scholar
• Fogelman S, Schmider J, Greenblatt DJ, Shader RI (1995) Metabolism of venlafaxine: the role of P450 isoforms (abstract). J Clin Pharmacol 35: 936.
   Google Scholar
• Otton SV Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalyzed by CYP2D6. BrJ Clin Pharmacol 41: 149–56.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Wrigth CE (1993) Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 24: 453–71.
   PubMed Web of Science ®Google Scholar
• Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephentoin hydroxylase and CYP3A isoforms. BrJ Clin Pharmacol 28: 131–7.
   Google Scholar
• Ball SE, Ahern D, Scatina J, Kao J (1997) Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism: comparative studies with selected SSRIs and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 43: 619–26.
   PubMed Web of Science ®Google Scholar
• Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C (1985) Pharmacokinetic concequences of long term co-administration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healty subjects. Int J Clin Pharmacol Ther Toxicol 23: 447—51.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS (1992) Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 52: 479–86.
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46: 35–9.
   PubMed Web of Science ®Google Scholar
• Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995) Coadministration of nefazodone and benzodiazepines III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15: 399–407.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Morse DS, Shader RI (1985) Interaction of propoxyphene with diazepam, alprazolam and lorazepam. BrJ Clin Pharmacol 19: 51–7.
   PubMed Web of Science ®Google Scholar
• Kelsey JE, Nemeroff CB (2000) Selective serotonin reuptake inhibitors. In: Sadock BJ, Sadock VA (eds) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 7th edn. Philadelphia: Lippincott/Williams & Wilkins: 2432—4.
   Google Scholar
• Hobbs WR, Rall TW, Verdoorn TA (1996) Hypnotics and sedatives; ethanol. In: Hardman JG, Goodman Gilman A, Limbird LE (eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9th edn. International edition. McGraw-Hill, New York, 361—396.
   Google Scholar
• Ranieri P, Franzoni S, Trabucchi M (1999) Alprazolam and hypotension. Int Geriatr Psychiatry 14: 401–2.
   PubMed Web of Science ®Google Scholar
• Enero MA, Solignac D, Apud JA (1988) Studies on the GABAergic system in cardiovascular control in normotensive and in sinoaortic denervated rats. Clin Exp Hypertens A 10 (Suppl 1): 331–7.
   PubMedGoogle Scholar
• Singhi S, Murthy A, Singhi P, Jayashree M (2002) Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol 17: 106—10.
   PubMed Web of Science ®Google Scholar
• Fait ML, Wise MG, Jachna JS, Lane RD, Gelenberg AJ (2002) Psychopharmacology In: Wise MG, Rundell JR (eds) Textbook of Consultation-Liason Psychiatry, 2nd edn. Washington: American Psychiatric Publishing: 939—87.
   Google Scholar
• Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991) Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23: 191–9.
   Web of Science ®Google Scholar
• Preskorn SH, Burke M (1992) Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 53 (Suppl 9): 5–18.
   PubMed Web of Science ®Google Scholar
• Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST (1992) Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 32: 716–24.
   PubMed Web of Science ®Google Scholar
• Janicak PG, Davis JM, Preskorn SH, Ayd FJ (1997) Principles and Practice of Psychopharmacotherapy, 2nd edn. Baltimore: Williams & Wilkins: 302—6.
   Google Scholar
• Haskins JT, Moyer JA, Muth EA, Sigg EB (1985) DMI, WY-45,030, WY-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol 115: 139–46.
   PubMed Web of Science ®Google Scholar
• Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO (1994) Polymorphic debrisoquin metabolism in a Turkish population. Clin Pharmacol Ther 55: 399–401.
   PubMed Web of Science ®Google Scholar
• Aynacıoglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schroder T, Kayaalp SO, Roots I, Brockmoller J (1999) Low frequency of defective alleles of cytochrome P 450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 66: 185 — 92.
   Google Scholar
• Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM (1998) Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 34: 211–9.
   PubMedGoogle Scholar
• Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38: 41—57.
   PubMed Web of Science ®Google Scholar
• Hodge CW, Mehmert KK, Kelley SP, McMahon T, Haywood A, Olive MF, Wang D, Sanchez-Perez AM, Messing RO (1999) Supersensitivity to allosteric GABA (A) receptor modulators and alcohol in mice lacking PKCepsilon. Nat Neurosci 2: 997—1002.
   PubMed Web of Science ®Google Scholar
• Baraldi M, Zeneroli ML, Ventura E, Vezzelli C (1987) An increase in cerebral benzodiazepine receptors induced by a subacute administration of ammonia, mercaptans and short-chain fatty acids in rats. Clin Sci 73: 669—71.
   Web of Science ®Google Scholar
• Wu PH, Coffin VL (1984) Up-regulation of brain [3H] diazepam binding sites in chronic caffeine-treated rats. Brain Res 294: 186 — 9.
   Google Scholar